Response to ‘D276G mutation is associated with a poor prognosis in imatinib mesylate-resistant chronic myeloid leukemia patients’ by Leguay et al

被引：0
|
作者：
R G Piazza
V Magistroni
A Franceschino
C Gambacorti-Passerini
机构：
[1] S. Gerardo Hospital,Department of Oncology
[2] University of Milano Bicocca,undefined
[3] Section of Hematology,undefined
[4] S. Gerardo Hospital,undefined
[5] McGill University,undefined
来源：
Leukemia | 2005年 / 19卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2333 / 2334
页数：1
相关论文
共 24 条
  • [21] Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase
    Fava, Carmen
    Kantarjian, Hagop M.
    Jabbour, Elias
    O'Brien, Susan
    Jain, Nitin
    Rios, Mary Beth
    Garcia-Manero, Guillermo
    Ravandi, Farhad
    Verstovsek, Srdan
    Borthakur, Gautam
    Shan, Jianqin
    Cortes, Jorge
    BLOOD, 2009, 113 (21) : 5058 - 5063
  • [22] Correlation of clinical response to dasatinib (BMS-354825) with BCR-ABL mutation status in imatinib-resistant patients (pts) with chronic myeloid leukemia (CML) treated at MD Anderson cancer center (MDACC).
    Jabbour, E
    Cortes, J
    Talpaz, M
    Jones, D
    O'Brien, S
    Nicaise, C
    Kantarjian, H
    BLOOD, 2005, 106 (11) : 318A - 318A
  • [23] The Novel BCR-ABL1 V304D Mutation Induces Pan-Tyrosine Kinase Inhibitor Resistance by a Unique Kinase Lateral Escape Mechanism and Is Associated with Very Poor Prognosis In Patients (PTS) with Chronic Myeloid Leukemia (CML)
    Pricl, Sabrina
    Gibbons, Don L.
    Posocco, Paola
    Laurini, Erik
    Fermeglia, Maurizio
    Kantarjian, Hagop M.
    Talpaz, Moshe
    Cortes, Jorge
    Young, Matthew
    Sun, Hanshi
    Peterson, Luke F.
    Donato, Nicholas
    Quintas-Cardama, Alfonso
    BLOOD, 2010, 116 (21) : 1392 - 1393
  • [24] Correlation of clinical response to BMS-354825 with BCR-ABL mutation status in imatinill-resistant patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-associated acute lymphoblastic leukemia (Ph plus ALL).
    Shah, N
    Sawyers, CL
    Kantarjian, HMM
    Donato, N
    Nicoll, J
    Cortes, J
    Paquette, R
    Huang, F
    Clark, E
    Talpaz, M
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 565S - 565S
123